Progeneer Looks To Disrupt Cell-Free Protein Synthesis Landscape
Individualized Oncovaccine Against BCL
Executive Summary
Progeneer CEO Chul Kim talks to Scrip about how the Korean bioventure aims to make a difference in cell-free protein synthesis and vaccine adjuvant systems to become a game changer.